Incannex Healthcare Inc. Common Stock (IXHL)
Stock · NASDAQ · Health Care
$2.83as of 10/16/2026
Price chart
Active signals
IXHL Signal Track Record
How signals performed across all stocks →What IXHL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 16 | -15.1% | 38% | February 25, 2026 |
| Bollinger Band Breakout | 14 | -16.6% | 29% | August 19, 2026 |
| Volume Spike | 12 | -20.2% | 17% | September 1, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -38.6% | 0% | July 28, 2025 |
| Any 20-session window (baseline) | -7.8% | 36% |
Computed by MarketWall from daily closing prices since December 14, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IXHL
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treat…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 12
- Website
- www.incannex.com
Fundamentals
- 1-day range
- $2.75$2.89
- Market cap
- $37.21M
- P/E (trailing)
- —
- P/E (forward)
- -1.69
- EPS (trailing)
- $-1.70
- Dividend yield
- —
- Beta
- 1.83
- Avg. volume
- 87.9K
How Incannex Healthcare Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Sep 29, 2025 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Incannex Healthcare Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IXHLIncannex Healthcare Inc. Common Stock$2.82▼ 2.08%Market cap $37.21MP/E —$2.49$14.91
- CRVOCervoMed Inc. Common Stock$2.24▼ 0.44%Market cap $37.33MP/E —$2.13$10
- APLMApollomics Inc. Class A Ordinary Shares$21.1▲ 0.48%Market cap $37.33MP/E —$10.01$42.12
- VERUVeru Inc. Common Stock$2.3▼ 5.74%Market cap $37.08MP/E —$2.05$7.33
- BYSIBeyondSpring Inc. Ordinary Shares$0.559▼ 3.95%Market cap $35.77MP/E —$0.5657$2.44
- NNVCNanoViricides Inc. Common Stock$1.38▲ 0.73%Market cap $35.56MP/E —$0.85$2.23
- LTRNLantern Pharma Inc. Common Stock$0.668▲ 0.15%Market cap $35.47MP/E —$0.651$4.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IXHL Incannex Healthcare Inc. Common Stock | $37.21M | — | $2.82 | ▼ 2.08% | $2.49$14.91 |
| CRVO CervoMed Inc. Common Stock | $37.33M | — | $2.24 | ▼ 0.44% | $2.13$10 |
| APLM Apollomics Inc. Class A Ordinary Shares | $37.33M | — | $21.1 | ▲ 0.48% | $10.01$42.12 |
| VERU Veru Inc. Common Stock | $37.08M | — | $2.3 | ▼ 5.74% | $2.05$7.33 |
| BYSI BeyondSpring Inc. Ordinary Shares | $35.77M | — | $0.559 | ▼ 3.95% | $0.5657$2.44 |
| NNVC NanoViricides Inc. Common Stock | $35.56M | — | $1.38 | ▲ 0.73% | $0.85$2.23 |
| LTRN Lantern Pharma Inc. Common Stock | $35.47M | — | $0.668 | ▲ 0.15% | $0.651$4.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26Yahoo · 10/1/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.29M
- Total value held
- $3.82M
- Institutional holders
- 19
- Unknown625.0K
- Unknown162.9K
- Unknown149.9K
- Unknown104.1K
- Unknown73.2K
- Unknown71.2K
- Unknown40.4K
- Unknown24.5K
- Unknown16.2K
- Unknown12.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Stonegate Updates Coverage on Incannex Healthcare (IXHL)
Stonegate has updated its coverage of Incannex Healthcare for fiscal year 2026. The stock is currently trading within a wide 52-week range, with the recent price action near the $3.16 support level providing context for this analyst update. The single available analyst target remains significantly higher than the current trading price.
Stonegate Updates Coverage on Incannex Healthcare (IXHL). Stonegate has updated its coverage of Incannex Healthcare for fiscal year 2026. The stock is currently trading within a wide 52-week range, with the recent price action near the $3.16 support level providing context for this analyst update. The single available analyst target remains significantly higher than the current trading price.